ACCRU-ITOG-1504 Achieves Accrual Goal
Congratulations to Principal Investigator: Bryan Haugen at The University of Colorado Cancer Center and his team for achieving accrual goal of 60 ACCRU-ITOG-1504: Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study.
Recent Posts
Catch up on the latest from ITOG—research progress, community updates, and highlights shaping the future of thyroid [...]
2024 Robert F. Gagel ITOG Discovery Award Winner: Jim Fagin, MD for “Leveraging therapeutic vulnerabilities induced by [...]
